Grandfield & Dodd, LLC Pds Biotechnology Corp Transaction History
Grandfield & Dodd, LLC
- $1.61 Billion
- Q2 2025
A detailed history of Grandfield & Dodd, LLC transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 10,000 shares of PDSB stock, worth $9,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$9,500% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PDSB
# of Institutions
60Shares Held
7.71MCall Options Held
98.2KPut Options Held
0-
Armistice Capital, LLC New York, NY2.24MShares$2.12 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.85 Million0.0% of portfolio
-
Ubs Group Ag543KShares$515,8690.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$462,6180.0% of portfolio
-
Geode Capital Management, LLC Boston, MA418KShares$397,0370.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $27M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...